2.22
7.25%
0.15
After Hours:
2.23
0.010
+0.45%
Gain Therapeutics Inc stock is traded at $2.22, with a volume of 191.97K.
It is up +7.25% in the last 24 hours and up +21.98% over the past month.
Gain Therapeutics Inc is a biotechnology company developing novel small molecule therapeutics to treat diseases across, several therapeutics areas, including, lysosomal storage disorders, central nervous system disorders, metabolic disorders, and oncology. The company's clinical-stage product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson's disease. The company uses its computational target and drug discovery platform, Magellan, to discover novel allosteric binding sites on proteins implicated in disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. The company derives revenues from collaboration and licensing agreements.
See More
Previous Close:
$2.07
Open:
$2.06
24h Volume:
191.97K
Relative Volume:
0.48
Market Cap:
$57.45M
Revenue:
$210.70K
Net Income/Loss:
$-22.22M
P/E Ratio:
-1.2198
EPS:
-1.82
Net Cash Flow:
$-17.13M
1W Performance:
-13.62%
1M Performance:
+21.98%
6M Performance:
-25.00%
1Y Performance:
-22.65%
Gain Therapeutics Inc Stock (GANX) Company Profile
Name
Gain Therapeutics Inc
Sector
Industry
Phone
(301) 500-1556
Address
4800 HAMPDEN LANE, BETHESDA
Gain Therapeutics Inc Stock (GANX) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Apr-12-21 | Initiated | BTIG Research | Buy |
Apr-12-21 | Initiated | Oppenheimer | Outperform |
Gain Therapeutics Inc Stock (GANX) Latest News
2024's 10 Best-Performing Stocks | Investing - U.S News & World Report Money
Hoping for a weight-loss pill? It could get closer to reality next week. - MarketWatch
individual investors who own 55% along with institutions invested in Sangamo Therapeutics, Inc. (NASDAQ:SGMO) saw increase in their holdings value last week - Yahoo Finance
Amneal Pharmaceuticals (NASDAQ:AMRX) grows 3.0% this week, taking five-year gains to 211% - Yahoo Finance
Short Interest in Gain Therapeutics, Inc. (NASDAQ:GANX) Decreases By 12.6% - MarketBeat
Vertex Pharmaceuticals (VRTX) Stock Drops Despite Market Gains: Important Facts to Note - Yahoo Finance
Nuclear stocks gain on AI optimism: Oklo, NuScale, Centrus - Yahoo Finance
Investing in Arcturus Therapeutics Holdings (NASDAQ:ARCT) five years ago would have delivered you a 76% gain - Yahoo Finance
Gain Therapeutics Presents Data at 36ᵗʰ EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics Demonstrating Identification of Allosteric Inhibitors Targeting DDR2 - The Manila Times
What Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) 26% Share Price Gain Is Not Telling You - Simply Wall St
Gain Therapeutics Regains Nasdaq Compliance - Investing.com
Gain Therapeutics Regains Nasdaq Compliance By Investing.com - Investing.com UK
Viking Therapeutics, Inc. (VKTX) Exceeds Market Returns: Some Facts to Consider - MSN
32 NMEs gain US FDA clearance through Q3, approvals up over 2023 - BioWorld Online
Viking Therapeutics, Inc. (VKTX) Outpaces Stock Market Gains: What You Should Know - MSN
How should investors view Janux Therapeutics Inc (JANX)? - US Post News
What was Gain Therapeutics Inc (GANX)’s performance in the last session? - US Post News
Gain Therapeutics Inc [GANX] Investment Guide: What You Need to Know - Knox Daily
GANX Stock: A Voyage Through Gain Therapeutics Inc’s Finances - The InvestChronicle
Can you now get a good deal on Compass Therapeutics Inc’s shares? - US Post News
Gain Therapeutics Announces Poster Presentation at 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics - The Manila Times
Renaissance Technologies LLC Boosts Holdings in Exagen Inc. (NASDAQ:XGN) - Defense World
Renaissance Technologies LLC Has $152,000 Stock Position in Gain Therapeutics, Inc. (NASDAQ:GANX) - Defense World
Investing in Voyager Therapeutics (NASDAQ:VYGR) three years ago would have delivered you a 58% gain - Yahoo Finance
Boeing, Nurix Therapeutics And 3 Stocks To Watch Heading Into Monday - Benzinga
Edgewise Therapeutics Inc (EWTX) Stock: Navigating Drops and Gains - The InvestChronicle
Seres Therapeutics gains amid takeover speculation - Seeking Alpha
GT-02287 may slow Parkinson’s progression, new early data suggest - Parkinson's News Today
Soleno Therapeutics Inc [SLNO] Revenue clocked in at $0.00 million, up 29.12% YTD: What’s Next? - The DBT News
PTC Therapeutics (PTCT) Surges 16.5%: Is This an Indication of Further Gains? - Yahoo
Gain Therapeutics to Present at Michael J. Fox Foundation's 16th Annual Parkinson's Disease Therapeutics Conference - The Manila Times
Gain Therapeutics to Present at Michael J. Fox Foundation’s 16th Annual Parkinson’s Disease Therapeutics Conference - Yahoo Finance
Belite Delights Investors, Soleno, ADMA, Harrow Deliver Triple-digit Gains, Keep An Eye On Oculis - RTTNews
Gain Therapeutics Announces Positive Preclinical Data for GT-02287 - Defense World
CRISPR Therapeutics AG (CRSP) Stock Sinks As Market Gains: Here's Why - Yahoo Finance
Gain Therapeutics Excels in Neurodegenerative Drug Trials - TipRanks
Gaining Ground: Aptevo Therapeutics Inc (APVO) Closes Lower at 0.16, Down -2.60 - The Dwinnex
GANX’s Financial Health: Exploring Gain Therapeutics Inc’s Debt-to-Equity Ratio of 1.79 - The InvestChronicle
Can you still get a good price for Mersana Therapeutics Inc (MRSN) Shares at this point? - US Post News
Robinhood Markets Inc [HOOD] Stock sold by Insider Gallagher Daniel Martin Jr for $0.28 million - Knox Daily
GT-02287 shows promise in Parkinson's disease models - Investing.com
Small-Cap Gain Therapeutics Stock Falls On Phase 1 Data From Its Lead Asset For Parkinson's Disease - MSN
Three startups aim to raise $400 million as US biotech IPOs gain traction - Yahoo Finance
Market Insight: Fate Therapeutics Inc (FATE)’s Notable Gain, Closing at 3.22 - The Dwinnex
Three startups aim to raise $400 mln as US biotech IPOs gain traction - Reuters
Gaining Ground: Seres Therapeutics Inc (MCRB) Closes Higher at 0.85, Up 1.35 - The Dwinnex
Gain Therapeutics Presents Preclinical GT-02287 Data at Neuroscience 2024 - The Manila Times
GT-02287 shows promise in Parkinson's disease models By Investing.com - Investing.com UK
Can you still get a good price for Denali Therapeutics Inc (DNLI) Shares at this point? - US Post News
Applied Therapeutics Inc (APLT) Stock: A 52-Week Tale of Drops and Gains - The InvestChronicle
Gain Therapeutics to Participate at Upcoming Investor Conferences - The Manila Times
Gain Therapeutics Inc Stock (GANX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):